BBA
MRNS

Baker Bros. Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Baker Bros. Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-50,000
Closed -$1.53M – 136
2015
Q4 		$1.53M Hold
50,000
– – 0.01% 113
2015
Q3 		$1.67M Hold
50,000
– – 0.02% 110
2015
Q2 		$2.32M Hold
50,000
– – 0.02% 97
2015
Q1 		$1.8M Sell
50,000
-1,119
-2% -$49.1K 0.02% 108
2014
Q4 		$2.16M Hold
51,119
– – 0.02% 100
2014
Q3 		$1.32M Buy
+51,119
New +$1.58M 0.02% 96

Other funds holding MRNS

CPV
Canaan Partners VII Westport, Connecticut $32.3M AUM 154.97% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baker Bros. Advisors's MRNS Position: Q1 2016 in Review

Baker Bros. Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2016, closing a stake of 50,000 shares — an estimated $1.53M sold.

Baker Bros. Advisors first reported a position in MRNS in Q3 2014 and held it in 6 quarters. The position peaked at $2.32M in Q2 2015. 31 funds tracked by Wall St. Rank hold MRNS as of Q1 2016.

  • Baker Bros. Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2016 after selling out during the quarter.
  • Baker Bros. Advisors sold 50,000 Marinus Pharmaceuticals, Inc shares in Q1 2016, an estimated $1.53M.
  • Baker Bros. Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q3 2014 and held it in 6 quarters.
  • Baker Bros. Advisors's Marinus Pharmaceuticals, Inc position peaked at $2.32M in Q2 2015.
  • 31 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2016.

Based on Baker Bros. Advisors's 13F filing for Q1 2016, filed 16 May 2016.